This is a preclinical materials science study reporting rational design and in vitro/in vivo characterization of a nanoagent; it raises mechanistic questions about nanoparticle performance but does not test efficacy against a comparator in any clinical or disease model.
Preclinical proof-of-concept study in cell culture and animal models demonstrating a novel composite material's ability to modulate the tumor microenvironment and enhance immune engagement; no human data or clinical endpoints reported.
This is a proof-of-concept study of a novel photosensitizer design in a single tumor model with intratumoral dosing and short-term follow-up, demonstrating feasibility but lacking comparator arms, efficacy benchmarking, or systemic biodistribution data needed to establish clinical potential.
In vivo proof-of-concept in a mouse NPC model with surrogate immunological endpoints and tumor growth inhibition, but lacking clinical translation, long-term safety data, and human validation.
In vitro proof-of-concept study of a novel hydrogel material platform with demonstrated drug release and cancer cell cytotoxicity, but no animal or clinical data; requires substantial further development before clinical relevance can be assessed.